These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 37437537)

  • 1. Innate immunity and interferon in SARS-CoV-2 infection outcome.
    Savan R; Gale M
    Immunity; 2023 Jul; 56(7):1443-1450. PubMed ID: 37437537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
    Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 Evasion of the Interferon System: Can We Restore Its Effectiveness?
    Sacchi A; Giannessi F; Sabatini A; Percario ZA; Affabris E
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective Potentials of Type III Interferons in COVID-19 Patients: Lessons from Differential Properties of Type I- and III Interferons.
    Jafarzadeh A; Nemati M; Saha B; Bansode YD; Jafarzadeh S
    Viral Immunol; 2021 Jun; 34(5):307-320. PubMed ID: 33147113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 Isolates Show Impaired Replication in Human Immune Cells but Differential Ability to Replicate and Induce Innate Immunity in Lung Epithelial Cells.
    Jiang M; Kolehmainen P; Kakkola L; Maljanen S; Melén K; Smura T; Julkunen I; Österlund P
    Microbiol Spectr; 2021 Sep; 9(1):e0077421. PubMed ID: 34378952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased Sensitivity of SARS-CoV-2 to Type III Interferon in Human Intestinal Epithelial Cells.
    Metz-Zumaran C; Kee C; Doldan P; Guo C; Stanifer ML; Boulant S
    J Virol; 2022 Apr; 96(7):e0170521. PubMed ID: 35262371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The battle between host and SARS-CoV-2: Innate immunity and viral evasion strategies.
    Zhang S; Wang L; Cheng G
    Mol Ther; 2022 May; 30(5):1869-1884. PubMed ID: 35176485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential roles of interferons in innate responses to mucosal viral infections.
    Walker FC; Sridhar PR; Baldridge MT
    Trends Immunol; 2021 Nov; 42(11):1009-1023. PubMed ID: 34629295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The RNA sensor MDA5 detects SARS-CoV-2 infection.
    Sampaio NG; Chauveau L; Hertzog J; Bridgeman A; Fowler G; Moonen JP; Dupont M; Russell RA; Noerenberg M; Rehwinkel J
    Sci Rep; 2021 Jul; 11(1):13638. PubMed ID: 34211037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A hybrid discrete-continuum model of immune responses to SARS-CoV-2 infection in the lung alveolar region, with a focus on interferon induced innate response.
    Aristotelous AC; Chen A; Forest MG
    J Theor Biol; 2022 Dec; 555():111293. PubMed ID: 36208668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic Options.
    Znaidia M; Demeret C; van der Werf S; Komarova AV
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type I and III interferon responses in SARS-CoV-2 infection.
    Kim YM; Shin EC
    Exp Mol Med; 2021 May; 53(5):750-760. PubMed ID: 33953323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of impairment of interferon production by SARS-CoV-2.
    Hoang HD; Naeli P; Alain T; Jafarnejad SM
    Biochem Soc Trans; 2023 Jun; 51(3):1047-1056. PubMed ID: 37199495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon antagonists encoded by SARS-CoV-2 at a glance.
    Lee JH; Koepke L; Kirchhoff F; Sparrer KMJ
    Med Microbiol Immunol; 2023 Apr; 212(2):125-131. PubMed ID: 35366686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING signaling pathways.
    Han L; Zhuang MW; Deng J; Zheng Y; Zhang J; Nan ML; Zhang XJ; Gao C; Wang PH
    J Med Virol; 2021 Sep; 93(9):5376-5389. PubMed ID: 33913550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19.
    Lowery SA; Sariol A; Perlman S
    Cell Host Microbe; 2021 Jul; 29(7):1052-1062. PubMed ID: 34022154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 NSP7 inhibits type I and III IFN production by targeting the RIG-I/MDA5, TRIF, and STING signaling pathways.
    Deng J; Zheng Y; Zheng SN; Nan ML; Han L; Zhang J; Jin Y; Pan JA; Gao C; Wang PH
    J Med Virol; 2023 Mar; 95(3):e28561. PubMed ID: 36755358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aging and Interferons: Impacts on Inflammation and Viral Disease Outcomes.
    Feng E; Balint E; Poznanski SM; Ashkar AA; Loeb M
    Cells; 2021 Mar; 10(3):. PubMed ID: 33806810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 Nonstructural Protein 1 Inhibits the Interferon Response by Causing Depletion of Key Host Signaling Factors.
    Kumar A; Ishida R; Strilets T; Cole J; Lopez-Orozco J; Fayad N; Felix-Lopez A; Elaish M; Evseev D; Magor KE; Mahal LK; Nagata LP; Evans DH; Hobman TC
    J Virol; 2021 Jun; 95(13):e0026621. PubMed ID: 34110264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.